We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Active Biotech AB has reached a manufacturing agreement with Famar Health Care Services Madrid SAU, a European provider of pharmaceutical manufacturing and development services.
Laquinimod, an orally administered small molecule has primarily been developed as a potential treatment of neurodegenerative diseases such as multiple sclerosis (MS) and Huntington's disease (HD).